ORGO logo

ORGANOGENESIS HOLDINGS INC

ORGONASDAQ
๐Ÿ† #3942 by market capEarnings Nov 5US Equity
$0.82โ–ฒ $0.00 (+0.08%)
After hours ยท at close
๐Ÿ””
Track ORGO
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 0.1%
7dโ–ผ 20.7%
14dโ–ผ 25.4%
30dโ–ผ 40.5%
ytdโ–ผ 84.1%
1yโ–ผ 80.2%
๐ŸฆMarket Cap
$106M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
6.5%
Slowing
๐Ÿ“ŠGross Margin
70.3%
High
๐Ÿ’ตFCF Margin
11.7%
Healthy
โš–๏ธP/S Ratio
0.2x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.81 โ€“ $0.86
52-Week Range
$0.81 โ€“ $7.08
Volume (shares)
48,708
Avg Volume (shares)
โ€”
Shares Outstanding
128.7M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
0.2x
EPS (TTM)
$-0.69
Dividend Yield
โ€”
ORGO logo

ORGANOGENESIS HOLDINGS INC

ORGO
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ORGANOGENESIS HOLDINGS INC

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Sell
7 analysts
Strong Buy0
Buy0
Hold4
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.